Investor Relations
Medinice has been discovering, developing, and researching medical devices in the field of cardiology and cardiac surgery for over 10 years. Our commitment is focused on designing minimally invasive solutions that improve the patient’s quality of life. Leveraging our scientific and engineering expertise, we prototype first-in-class medical devices aimed at providing effective therapies for a broad spectrum of recipients. Medinice boasts a diverse portfolio of projects conducted with the support of the Scientific Council and various scientific and research institutions from Poland and around the world.
Shareholder structure
| Shareholder | Nr. of shares | % votes at AGM |
|---|---|---|
| Parmanand Private Trust (Sanjeev Choudhary) | 1 513 544 | 19% |
| Suwalski Piotr | 472 408 | 6% |
| Pozostali Akcjonariusze | 5 676 339 | 93% |
| Total | 7 662 291 | 100% |
Share price
Investor’s schedule
| Data | Periodic report |
|---|---|
| 28.03.2024 | Jednostkowy oraz skonsolidowany raport roczny za 2023 r. |
| 28.05.2024 | Consolidated and standalone periodic report for Q1 2024 r. |
| 22.08.2024 16.08.2024 | Skonsolidowany raport okresowy za I półrocze 2024 r. (data zmieniona ESPI 24/2024) |
| 22.11.2024 | Consolidated and separate periodic report for Q3 2024 r. |
Polityka dywidendowa
Management Board of Medinice S.A. on July 1, 2019 adopted a resolution on the Company’s dividend policy. If the Company earns a profit that may be allocated for distribution, the Company’s Management Board intends to submit a dividend payment proposal to the Ordinary General Meeting each year in accordance with the following parameters:
| Amount of profit to be divided | dividend sum |
|---|---|
| 15.000.000 – 50.000.000 PLN | at least 50% of the amount of profit to be distributed |
| 50.000.000 – 100.000.000 PLN | at least 60% of the amount of profit to be distributed |
| over 100.000.000 PLN | at least 75% of the amount of profit to be distributed |
Medinice group structure
